| Date:                 | 3.7.2022  |
|-----------------------|---|
| Your Names: _         | Michael Wyatt   |
|                       |   |
| <b>Manuscript Tit</b> | le: An age and sex matched study on the effect of obesity on the functional outcomes and complication |
| rates in patien       | ts with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion            |
| Manuscript nu         | mber (if known): AOJ-22-14  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:            | 3.7.2022   |
|------------------|--|
| Your Names:      | David Keiser   |
| rates in patient | e: An age and sex matched study on the effect of obesity on the functional outcomes and complication is with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion mber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:           | 3.7.2022   |
|-----------------|--|
| Your Names: _   | Louis Boissierem   |
| rates in patien | tle: An age and sex matched study on the effect of obesity on the functional outcomes and complication ats with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion amber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:           | 3.7.20                              | 22  |
|-----------------|-------------------------------------|---|
| Your Names: _   | Kazunori Hayashi                    |   |
| rates in patien | ts with adult spinal deformity unde | on the effect of obesity on the functional outcomes and complication ergoing primary multi-level thoraco-lumbar spinal fusion |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:          |                  | 3.7.2022  |  |  |
|----------------|------------------|-----------|--|--|
| Your Names:    | Derek Cawley     |           |  |  |
| •              | O                | · ·       | obesity on the functional outcomes and<br>y multi-level thoraco-lumbar spinal fu |  |
| Manuscript nur | nber (if known): | AOJ-22-14 |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |  |
|------|---|--------------------------------|------------|--|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |  |
|      | speakers bureaus,                                 |                                |            |  |  |
|      | manuscript writing or                             |                                |            |  |  |
|      | educational events                                |                                |            |  |  |
| 6    | Payment for expert                                | None                           |            |  |  |
|      | testimony   |                                |            |  |  |
| _    |   |                                |            |  |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |  |
|      | -   |                                |            |  |  |
|      |   |                                |            |  |  |
| 8    | Patents planned, issued or                        | None                           |            |  |  |
|      | pending   |                                |            |  |  |
|      |   |                                |            |  |  |
| 9    | Participation on a Data                           | None                           |            |  |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |  |
|      | committee or advocacy                             |                                |            |  |  |
|      | group, paid or unpaid                             |                                |            |  |  |
| 11   | Stock or stock options                            | None                           |            |  |  |
|      |   |                                |            |  |  |
| 42   | D   | N.                             |            |  |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |  |
|      | writing, gifts or other                           |                                |            |  |  |
|      | services  |                                |            |  |  |
| 13   | Other financial or non-                           | None                           |            |  |  |
|      | financial interests                               |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |  |
| n    | none  |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |

| Date:            | 3.7.2022      |  |    |
|------------------|---------------|--|----|
| Your Names:      | Caglar Yilgor |  |    |
| rates in patient | v             | fect of obesity on the functional outcomes and complication primary multi-level thoraco-lumbar spinal fusion | on |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |  |
|------|---|--------------------------------|------------|--|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |  |
|      | speakers bureaus,                                 |                                |            |  |  |
|      | manuscript writing or                             |                                |            |  |  |
|      | educational events                                |                                |            |  |  |
| 6    | Payment for expert                                | None                           |            |  |  |
|      | testimony   |                                |            |  |  |
| _    |   |                                |            |  |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |  |
|      | -   |                                |            |  |  |
|      |   |                                |            |  |  |
| 8    | Patents planned, issued or                        | None                           |            |  |  |
|      | pending   |                                |            |  |  |
|      |   |                                |            |  |  |
| 9    | Participation on a Data                           | None                           |            |  |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |  |
|      | committee or advocacy                             |                                |            |  |  |
|      | group, paid or unpaid                             |                                |            |  |  |
| 11   | Stock or stock options                            | None                           |            |  |  |
|      |   |                                |            |  |  |
| 42   | D   | N.                             |            |  |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |  |
|      | writing, gifts or other                           |                                |            |  |  |
|      | services  |                                |            |  |  |
| 13   | Other financial or non-                           | None                           |            |  |  |
|      | financial interests                               |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |  |
| n    | none  |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |

| Date:          |                  | 3.7.2022  |   |  |
|----------------|------------------|-----------|---|--|
| Your Names:    | Danier Larrieu   |           |   |  |
| •              | S                | v         | obesity on the functional outcomes and<br>ry multi-level thoraco-lumbar spinal fu |  |
| Manuscript nur | nber (if known): | AOJ-22-14 |   |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |  |
|------|---|--------------------------------|------------|--|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |  |
|      | speakers bureaus,                                 |                                |            |  |  |
|      | manuscript writing or                             |                                |            |  |  |
|      | educational events                                |                                |            |  |  |
| 6    | Payment for expert                                | None                           |            |  |  |
|      | testimony   |                                |            |  |  |
| _    |   |                                |            |  |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |  |
|      | -   |                                |            |  |  |
|      |   |                                |            |  |  |
| 8    | Patents planned, issued or                        | None                           |            |  |  |
|      | pending   |                                |            |  |  |
|      |   |                                |            |  |  |
| 9    | Participation on a Data                           | None                           |            |  |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |  |
|      | committee or advocacy                             |                                |            |  |  |
|      | group, paid or unpaid                             |                                |            |  |  |
| 11   | Stock or stock options                            | None                           |            |  |  |
|      |   |                                |            |  |  |
| 42   | D   | N.                             |            |  |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |  |
|      | writing, gifts or other                           |                                |            |  |  |
|      | services  |                                |            |  |  |
| 13   | Other financial or non-                           | None                           |            |  |  |
|      | financial interests                               |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |  |
| n    | none  |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |

| Date:           | 3.           | 7.2022 |   |  |
|-----------------|--------------|--------|---|--|
| Your Names:     | Ahmet Alanay |        |   |  |
| rates in patien | C            | •      | obesity on the functional outcomes and complication ry multi-level thoraco-lumbar spinal fusion |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |  |
|------|---|--------------------------------|------------|--|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |  |
|      | speakers bureaus,                                 |                                |            |  |  |
|      | manuscript writing or                             |                                |            |  |  |
|      | educational events                                |                                |            |  |  |
| 6    | Payment for expert                                | None                           |            |  |  |
|      | testimony   |                                |            |  |  |
| _    |   |                                |            |  |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |  |
|      | -   |                                |            |  |  |
|      |   |                                |            |  |  |
| 8    | Patents planned, issued or                        | None                           |            |  |  |
|      | pending   |                                |            |  |  |
|      |   |                                |            |  |  |
| 9    | Participation on a Data                           | None                           |            |  |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |  |
|      | committee or advocacy                             |                                |            |  |  |
|      | group, paid or unpaid                             |                                |            |  |  |
| 11   | Stock or stock options                            | None                           |            |  |  |
|      |   |                                |            |  |  |
| 42   | D   | N.                             |            |  |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |  |
|      | writing, gifts or other                           |                                |            |  |  |
|      | services  |                                |            |  |  |
| 13   | Other financial or non-                           | None                           |            |  |  |
|      | financial interests                               |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |  |
| n    | none  |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |
|      |   |                                |            |  |  |

| Date:            | 3.7.2022  |
|------------------|---|
| Your Names:      | Emre Acaroglu   |
| rates in patient | An age and sex matched study on the effect of obesity on the functional outcomes and complication with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion ber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:            | 3.7.2022   |
|------------------|--|
| Your Names:      | Frank Kleinstueck  |
| rates in patient | e: An age and sex matched study on the effect of obesity on the functional outcomes and complication its with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion mber (if known):  AOJ-22-14 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | needed) Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:            | 3.7.2022   |   |
|------------------|--|---|
| Your Names:      | Ferran Pellise   |   |
| rates in patient | e: An age and sex matched study on the effect of obesity on the functional outcomes and complications with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion mber (if known): | n |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:            | 3.7.2022  |
|------------------|---|
| Your Names:      | Francisco Perez-Grueso  |
| rates in patient | e: An age and sex matched study on the effect of obesity on the functional outcomes and complication s with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion ber (if known):  AOJ-22-14 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| Е    | Daymont or here are in fa-                        | None                           |            |  |
|------|---|--------------------------------|------------|--|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |  |
|      | speakers bureaus,                                 |                                |            |  |
|      | manuscript writing or                             |                                |            |  |
|      | educational events                                |                                |            |  |
| 6    | Payment for expert                                | None                           |            |  |
|      | testimony   |                                |            |  |
| _    |   |                                |            |  |
| 7    | Support for attending meetings and/or travel      | None                           |            |  |
|      | -   |                                |            |  |
|      |   |                                |            |  |
| 8    | Patents planned, issued or                        | None                           |            |  |
|      | pending   |                                |            |  |
|      |   |                                |            |  |
| 9    | Participation on a Data                           | None                           |            |  |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |  |
| 10   | Leadership or fiduciary role                      | None                           |            |  |
| 10   | in other board, society,                          | NOTIC                          |            |  |
|      | committee or advocacy                             |                                |            |  |
|      | group, paid or unpaid                             |                                |            |  |
| 11   | Stock or stock options                            | None                           |            |  |
|      |   |                                |            |  |
| 42   | D   | N.                             |            |  |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |  |
|      | writing, gifts or other                           |                                |            |  |
|      | services  |                                |            |  |
| 13   | Other financial or non-                           | None                           |            |  |
|      | financial interests                               |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |  |
| n    | none  |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |
|      |   |                                |            |  |

| Date:          | 3.7.2022  |
|----------------|---|
| Your Names:    | Anouar Bourghli   |
| •              | e: An age and sex matched study on the effect of obesity on the functional outcomes and complication ts with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion |
| Manuscript nui | mber (if known): AOJ-22-14  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| Е    | Daymont or here are in fa-                        | None                           |            |
|------|---|--------------------------------|------------|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |
|      | speakers bureaus,                                 |                                |            |
|      | manuscript writing or                             |                                |            |
|      | educational events                                |                                |            |
| 6    | Payment for expert                                | None                           |            |
|      | testimony   |                                |            |
| _    |   |                                |            |
| 7    | Support for attending meetings and/or travel      | None                           |            |
|      | -   |                                |            |
|      |   |                                |            |
| 8    | Patents planned, issued or                        | None                           |            |
|      | pending   |                                |            |
|      |   |                                |            |
| 9    | Participation on a Data                           | None                           |            |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |
| 10   | Leadership or fiduciary role                      | None                           |            |
| 10   | in other board, society,                          | NOTIC                          |            |
|      | committee or advocacy                             |                                |            |
|      | group, paid or unpaid                             |                                |            |
| 11   | Stock or stock options                            | None                           |            |
|      |   |                                |            |
| 42   | D   | N.                             |            |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |
|      | writing, gifts or other                           |                                |            |
|      | services  |                                |            |
| 13   | Other financial or non-                           | None                           |            |
|      | financial interests                               |                                |            |
|      |   |                                |            |
|      |   |                                |            |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |
| n    | one   |                                |            |
|      |   |                                |            |
|      |   |                                |            |
|      |   |                                |            |

| Date:          | 3.7              | 7.2022    |  |
|----------------|------------------|-----------|--|
| Your Names:    | Jean Vital       |           |  |
| -              | 0                | · ·       | sity on the functional outcomes and complication |
| Manuscript nur | nber (if known): | AOJ-22-14 | •  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| Е    | Daymont or here are in fa-                        | None                           |            |
|------|---|--------------------------------|------------|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |
|      | speakers bureaus,                                 |                                |            |
|      | manuscript writing or                             |                                |            |
|      | educational events                                |                                |            |
| 6    | Payment for expert                                | None                           |            |
|      | testimony   |                                |            |
| _    |   |                                |            |
| 7    | Support for attending meetings and/or travel      | None                           |            |
|      | -   |                                |            |
|      |   |                                |            |
| 8    | Patents planned, issued or                        | None                           |            |
|      | pending   |                                |            |
|      |   |                                |            |
| 9    | Participation on a Data                           | None                           |            |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |
| 10   | Leadership or fiduciary role                      | None                           |            |
| 10   | in other board, society,                          | NOTIC                          |            |
|      | committee or advocacy                             |                                |            |
|      | group, paid or unpaid                             |                                |            |
| 11   | Stock or stock options                            | None                           |            |
|      |   |                                |            |
| 42   | D   | N.                             |            |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |
|      | writing, gifts or other                           |                                |            |
|      | services  |                                |            |
| 13   | Other financial or non-                           | None                           |            |
|      | financial interests                               |                                |            |
|      |   |                                |            |
|      |   |                                |            |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |
| n    | one   |                                |            |
|      |   |                                |            |
|      |   |                                |            |
|      |   |                                |            |

| Date:            | 3.7.2022   |
|------------------|--|
| Your Names:      | Olicier Gille  |
| rates in patient | e: An age and sex matched study on the effect of obesity on the functional outcomes and complication ts with adult spinal deformity undergoing primary multi-level thoraco-lumbar spinal fusion mber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |
|------|---|--------------------------------|------------|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |
|      | speakers bureaus,                                 |                                |            |
|      | manuscript writing or                             |                                |            |
|      | educational events                                |                                |            |
| 6    | Payment for expert                                | None                           |            |
|      | testimony   |                                |            |
| _    |   |                                |            |
| 7    | Support for attending meetings and/or travel      | None                           |            |
|      | -   |                                |            |
|      |   |                                |            |
| 8    | Patents planned, issued or                        | None                           |            |
|      | pending   |                                |            |
|      |   |                                |            |
| 9    | Participation on a Data                           | None                           |            |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |
| 10   | Leadership or fiduciary role                      | None                           |            |
| 10   | in other board, society,                          | NOTIC                          |            |
|      | committee or advocacy                             |                                |            |
|      | group, paid or unpaid                             |                                |            |
| 11   | Stock or stock options                            | None                           |            |
|      |   |                                |            |
| 42   | D   | N.                             |            |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |
|      | writing, gifts or other                           |                                |            |
|      | services  |                                |            |
| 13   | Other financial or non-                           | None                           |            |
|      | financial interests                               |                                |            |
|      |   |                                |            |
|      |   |                                |            |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |
| n    | one   |                                |            |
|      |   |                                |            |
|      |   |                                |            |
|      |   |                                |            |

| Date:            | 3.7.2022   |   |
|------------------|--|---|
| Your Names:      | Ibrahim Obeid  |   |
| rates in patient | tle: An age and sex matched study on the effect of obesity on the sets with adult spinal deformity undergoing primary multi-level the timber (if known): | _ |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |

| Е    | Daymont or here are in fa-                        | None                           |            |
|------|---|--------------------------------|------------|
| 5    | Payment or honoraria for lectures, presentations, | None                           |            |
|      | speakers bureaus,                                 |                                |            |
|      | manuscript writing or                             |                                |            |
|      | educational events                                |                                |            |
| 6    | Payment for expert                                | None                           |            |
|      | testimony   |                                |            |
| _    |   |                                |            |
| 7    | Support for attending meetings and/or travel      | None                           |            |
|      | -   |                                |            |
|      |   |                                |            |
| 8    | Patents planned, issued or                        | None                           |            |
|      | pending   |                                |            |
|      |   |                                |            |
| 9    | Participation on a Data                           | None                           |            |
|      | Safety Monitoring Board or<br>Advisory Board      |                                |            |
| 10   | Leadership or fiduciary role                      | None                           |            |
| 10   | in other board, society,                          | NOTIC                          |            |
|      | committee or advocacy                             |                                |            |
|      | group, paid or unpaid                             |                                |            |
| 11   | Stock or stock options                            | None                           |            |
|      |   |                                |            |
| 42   | D   | N.                             |            |
| 12   | Receipt of equipment, materials, drugs, medical   | None                           |            |
|      | writing, gifts or other                           |                                |            |
|      | services  |                                |            |
| 13   | Other financial or non-                           | None                           |            |
|      | financial interests                               |                                |            |
|      |   |                                |            |
|      |   |                                |            |
| Plea | se summarize the above co                         | nflict of interest in the foll | owing box: |
| n    | one   |                                |            |
|      |   |                                |            |
|      |   |                                |            |
|      |   |                                |            |